# OnCo record zenocutuzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zenocutuzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zenocutuzumab" ;
  schema:name "Zenocutuzumab"@en ;
  schema:description "Zenocutuzumab is the first drug for cancers driven by NRG1 gene fusions, working by blocking HER3 from receiving its growth signal."@en ;
  schema:url <https://onco.cc/drugs/zenocutuzumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Zenocutuzumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q131471072> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zenocutuzumab>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BIZENGRI%22>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications>, <https://doi.org/10.1056/NEJMoa2405008> ;
  onco:status "approved" ;
  onco:modality "Bispecific antibody (HER2×HER3)" ;
  schema:alternateName "Bizengri" ;
  onco:approval "US 2024: NRG1-fusion NSCLC and pancreatic adenocarcinoma", "US 2026: NRG1-fusion cholangiocarcinoma" ;
  onco:acceleratedApproval "US 2024-12-04: Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.", "US 2024-12-04: Treatment of adults with advanced unresectable or metastatic nonsmall cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy." ;
  onco:related <https://onco.cc/biomarkers/nrg1-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/> ;
  onco:companies <https://onco.cc/companies/merus/> ;
  onco:trials <https://onco.cc/trials/nct02912949/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/>, <https://onco.cc/key-papers/paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/> .